(SNY) Sanofi - Overview
Stock: Vaccines, Insulin, Rare Disease Drugs, Oncology Drugs, Allergy Treatments
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.43% |
| Yield on Cost 5y | 5.66% |
| Yield CAGR 5y | 3.79% |
| Payout Consistency | 97.3% |
| Payout Ratio | 43.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 23.9% |
| Relative Tail Risk | -5.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.23 |
| Alpha | -12.59 |
| Character TTM | |
|---|---|
| Beta | 0.328 |
| Beta Downside | 0.186 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.87% |
| CAGR/Max DD | 0.22 |
Description: SNY Sanofi January 28, 2026
Sanofi (NASDAQ:SNY) is a global, integrated healthcare company that discovers, develops, manufactures, and markets therapeutic solutions across immunology & inflammation, rare diseases, neurology, oncology, and a broad vaccine portfolio that includes pediatric, respiratory syncytial virus, hexavalent, influenza, meningitis, and travel-endemic vaccines.
In FY 2025 the company reported €44.5 billion in total revenue, a 3.2 % year-over-year increase driven primarily by a 7 % rise in vaccine sales (up to €9.2 billion) and a 2 % lift in specialty pharmaceuticals; R&D spending reached €5.9 billion (13.2 % of revenue), reflecting continued investment in its oncology-immunology pipeline. These figures are taken from Sanofi’s Q4 2025 earnings release; actual FY 2025 results may be revised in the final filing.
Sanofi’s external innovation engine remains a strategic priority. Recent milestones include: the Exscientia partnership advancing three of its 15 planned small-molecule candidates into Phase II trials (oncology & immunology); ABL Bio’s ABL301 entering a pivotal Phase III study for Parkinson-related alpha-synucleinopathies; and the Innate Pharma NK-cell engager showing promising pre-clinical activity against B7-H3-positive solid tumours. All collaborations are subject to clinical risk and regulatory timelines.
Sector-wide drivers that materially affect Sanofi’s outlook are the aging global population (projected to increase demand for chronic-disease therapeutics by ~1.5 % CAGR through 2030), persistent vaccine-related public-health spending (global vaccine market expected to grow ~6 % CAGR, bolstered by pandemic-era preparedness), and tightening pricing pressures in major markets (e.g., EU reference pricing reforms). Sanofi’s diversified revenue mix buffers against any single-segment shock, but exposure to price-regulation remains a downside risk.
For a deeper quantitative dive, consult ValueRay’s dedicated SNY analysis page.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 7.81b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.62 > 1.0 |
| NWC/Revenue: 5.58% < 20% (prev 31.30%; Δ -25.72% < -1%) |
| CFO/TA 0.08 > 3% & CFO 10.75b > Net Income 7.81b |
| Net Debt (12.67b) to EBITDA (12.68b): 1.00 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.44b) vs 12m ago -2.65% < -2% |
| Gross Margin: 72.34% > 18% (prev 0.70%; Δ 7163 % > 0.5%) |
| Asset Turnover: 35.99% > 50% (prev 32.30%; Δ 3.69% > 0%) |
| Interest Coverage Ratio: 12.76 > 6 (EBITDA TTM 12.68b / Interest Expense TTM 742.0m) |
Beneish M -3.73
| DSRI: 0.03 (Receivables 396.8m/10.63b, Revenue 46.72b/42.89b) |
| GMI: 0.97 (GM 72.34% / 70.31%) |
| AQI: 1.12 (AQ_t 0.67 / AQ_t-1 0.59) |
| SGI: 1.09 (Revenue 46.72b / 42.89b) |
| TATA: -0.02 (NI 7.81b - CFO 10.75b) / TA 126.81b) |
| Beneish M-Score: -3.73 (Cap -4..+1) = AAA |
What is the price of SNY shares?
Over the past week, the price has changed by +2.12%, over one month by -1.55%, over three months by -4.72% and over the past year by -5.39%.
Is SNY a buy, sell or hold?
- StrongBuy: 5
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 58.2 | 20.6% |
| Analysts Target Price | 58.2 | 20.6% |
| ValueRay Target Price | 49.4 | 2.3% |
SNY Fundamental Data Overview February 09, 2026
P/E Forward = 9.6618
P/S = 2.4868
P/B = 1.3715
P/EG = 0.7208
Revenue TTM = 46.72b USD
EBIT TTM = 9.47b USD
EBITDA TTM = 12.68b USD
Long Term Debt = 11.70b USD (from longTermDebt, two quarters ago)
Short Term Debt = 4.61b USD (from shortTermDebt, last quarter)
Debt = 20.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.67b USD (from netDebt column, last quarter)
Enterprise Value = 128.85b USD (116.17b + Debt 20.33b - CCE 7.66b)
Interest Coverage Ratio = 12.76 (Ebit TTM 9.47b / Interest Expense TTM 742.0m)
EV/FCF = 15.49x (Enterprise Value 128.85b / FCF TTM 8.32b)
FCF Yield = 6.46% (FCF TTM 8.32b / Enterprise Value 128.85b)
FCF Margin = 17.80% (FCF TTM 8.32b / Revenue TTM 46.72b)
Net Margin = 16.72% (Net Income TTM 7.81b / Revenue TTM 46.72b)
Gross Margin = 72.34% ((Revenue TTM 46.72b - Cost of Revenue TTM 12.92b) / Revenue TTM)
Gross Margin QoQ = 70.26% (prev 74.09%)
Tobins Q-Ratio = 1.02 (Enterprise Value 128.85b / Total Assets 126.81b)
Interest Expense / Debt = 0.49% (Interest Expense 100.6m / Debt 20.33b)
Taxrate = 17.33% (1.04b / 6.02b)
NOPAT = 7.83b (EBIT 9.47b * (1 - 17.33%))
Current Ratio = 1.09 (Total Current Assets 30.95b / Total Current Liabilities 28.35b)
Debt / Equity = 0.28 (Debt 20.33b / totalStockholderEquity, last quarter 71.38b)
Debt / EBITDA = 1.00 (Net Debt 12.67b / EBITDA 12.68b)
Debt / FCF = 1.52 (Net Debt 12.67b / FCF TTM 8.32b)
Total Stockholder Equity = 72.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.02% (Net Income 7.81b / Total Assets 126.81b)
RoE = 10.82% (Net Income TTM 7.81b / Total Stockholder Equity 72.18b)
RoCE = 11.29% (EBIT 9.47b / Capital Employed (Equity 72.18b + L.T.Debt 11.70b))
RoIC = 8.48% (NOPAT 7.83b / Invested Capital 92.30b)
WACC = 6.12% (E(116.17b)/V(136.50b) * Re(7.12%) + D(20.33b)/V(136.50b) * Rd(0.49%) * (1-Tc(0.17)))
Discount Rate = 7.12% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.33%
[DCF Debug] Terminal Value 87.65% ; FCFF base≈7.08b ; Y1≈8.74b ; Y5≈14.88b
Fair Price DCF = 161.7 (EV 403.14b - Net Debt 12.67b = Equity 390.47b / Shares 2.42b; r=6.12% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 9.85 | EPS CAGR: 9.46% | SUE: 2.86 | # QB: 1
Revenue Correlation: 4.50 | Revenue CAGR: 5.31% | SUE: 1.24 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.06 | Chg30d=+0.070 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=5.01 | Chg30d=+0.060 | Revisions Net=+2 | Growth EPS=+7.3% | Growth Revenue=+6.5%
EPS next Year (2027-12-31): EPS=5.31 | Chg30d=-0.046 | Revisions Net=+0 | Growth EPS=+5.9% | Growth Revenue=+6.1%